Key Highlights

  • Net profit after tax was A$145.3 million, compared with a A$954.6 million loss in FY25.
  • Underlying EBITDA rose to A$285.9 million from a A$43.0 million loss a year earlier.
  • Revenue fell 12% to A$462.9 million, so the Earnings swing came mainly from lithium-linked businesses and the absence of prior-year write-downs.
  • A fully franked final Dividend of 5 cents per share was declared, and group cash was A$386.5 million with a A$300 million Facility undrawn.

What does it mean when a miner that booked a near-billion-dollar loss a year earlier reports an encouraging profit and a dividend? For IGO Limited (ASX:IGO), the FY26 result released on 27 August 2026 suggests a portfolio that has been simplified and is now earning from its lithium exposure, although the improvement is measured against a very weak base and the outlook still depends heavily on Commodity pricing and operational execution.

The central development: from loss to profit

Underlying EBITDA was A$285.9 million, against a A$43.0 million loss a year earlier. Revenue, however, fell 12% to A$462.9 million, which is a useful reminder that the earnings swing came largely from the equity-accounted lithium businesses and the absence of prior-year write-downs rather than from higher sales.

IGO declared a fully franked final dividend of 5 cents per share, costing about A$38 million, and reported group cash of A$386.5 million with a A$300 million corporate Debt facility undrawn.

The FY25 comparison matters. A loss of that size reflected impairments, so the swing to profit should be read as a recovery from a trough rather than a measure of sustained earnings power.

What IGO actually owns

IGO's value is concentrated in lithium. Through its stake in the Tianqi Lithium Energy Australia (TLEA) joint venture, it has exposure to the Greenbushes mine in Western Australia, widely regarded as one of the world's highest-grade spodumene operations, and to the Kwinana lithium hydroxide refinery. Greenbushes sells spodumene concentrate into the global battery chain; Kwinana converts concentrate into battery-grade hydroxide. Those are company-described arrangements; the exact ownership percentages are worth checking in IGO's Annual Report before relying on them.

For Kwinana, guidance points to lower costs and higher lithium hydroxide output. Kwinana has been the more troubled asset historically, with ramp-up difficulties and impairments, so improvement there is arguably the more important variable for the Investment case.

Portfolio pruning: Nova and Forrestania

IGO has been exiting nickel. If completed, the sales would leave IGO as an essentially lithium-plus-growth-options company, removing a high-cost commodity exposure that has weighed on earnings and attention.

Management's FY27 priorities, as summarised, are to close the Nova divestment and to focus growth on copper and lithium through exploration, BioHeap (a bioleaching technology IGO has been developing) and selective acquisitions. Dr Vanessa Guthrie AO has taken over as chair alongside other board changes.

Sector and competitive position

The lithium market has been through a painful supply-led downturn since 2023, with many higher-cost producers curtailing output. Greenbushes sits at the low end of the cost curve, which is the main reason IGO's exposure has held up better than that of many peers. The competitive question is less about Greenbushes itself and more about whether Downstream conversion at Kwinana can reach competitive cost and quality against Chinese refiners, which dominate global hydroxide supply.

IGO is not a pure-play operator: it holds minority-style exposure through a joint venture and therefore has limited control over mine plans, Capital spending and dividend flows. That structure can be a strength, given that Greenbushes is a world-class asset managed by an experienced operator, but it also limits IGO's ability to influence outcomes.

Material risks

Lithium price risk. Earnings are highly sensitive to spodumene and hydroxide prices, which have been volatile.

Kwinana execution. Further ramp-up problems or cost overruns would erode the recovery narrative.

Joint-venture dependence. IGO's cash returns depend on distributions and decisions within TLEA.

Divestment risk. The Nova sale is not yet complete, and conditions or delays could change the timeline.

Growth-strategy risk. Copper and BioHeap are earlier-stage and may need capital before they contribute.

Base effects. Year-on-year improvements flatter the picture because FY25 was unusually weak.

What to watch next

Key milestones include completion of the Nova sale in FY27, quarterly updates on Greenbushes volumes and Kwinana output, progress on copper and exploration spending, and any change to dividend policy or capital allocation priorities.

IGO's FY26 result confirms that the worst of the lithium-related write-downs is behind it for now. Whether that translates into durable earnings depends on factors outside management's direct control, which is why a careful reading of each quarterly update is more useful than any single headline.